An analysis of the trends, characteristics, scope, and performance of the Zimbabwean pharmacovigilance reporting scheme

dc.contributor.authorKhoza, Star
dc.contributor.authorMasuka, Josiah Tatenda
dc.date.accessioned2020-12-07T07:18:08Z
dc.date.available2020-12-07T07:18:08Z
dc.date.issued2020
dc.description.abstractWe aimed to determine the reporting trends and characteristics of Individual Case Safety Reports (ICSRs) from the Zimbabwean national pharmacovigilance system. ICSRs submitted to VigiBaseTM, the World Health Organisation's ICSR database between January 1993 and December 2017 were retrospectively reviewed with respect to the suspected medicine, System Organ Class (SOC), adverse drug reaction (ADR) type and seriousness, Anatomic Therapeutic Chemical (ATC) group, age, and gender. In total, 4071 ICSRs were submitted to VigiBaseTM from targeted spontaneous reporting (n = 2909; 71.5%), vaccine surveillance (n = 679; 16.7%), and passive spontaneous reporting (n = 483; 11.9%), respectivelyen_US
dc.identifier.citation4. Masuka, J. T., & Khoza, S. (2020). An analysis of the trends, characteristics, scope, and performance of the Zimbabwean pharmacovigilance reporting scheme. Pharmacology Research and Perspectives,8(5), e00657en_US
dc.identifier.issn2052-1707
dc.identifier.urihttps://doi.org/10.1002/prp2.657
dc.identifier.urihttp://hdl.handle.net/10566/5483
dc.language.isoenen_US
dc.publisherWiley-Blackwellen_US
dc.subjectAdverse drug reactionen_US
dc.subjectDrug safetyen_US
dc.subjectPharmacovigilanceen_US
dc.subjectPost-market surveillanceen_US
dc.subjectSpontaneous reporting systemen_US
dc.titleAn analysis of the trends, characteristics, scope, and performance of the Zimbabwean pharmacovigilance reporting schemeen_US
dc.typeArticleen_US

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
prp2.657.pdf
Size:
1.36 MB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: